Ts are rendered ineffective. Xyphos Biosciences has partnered with The Parker Institute for Cancer Immunotherapy to improve the safety and effectiveness of first-generation CAR-T therapies. Xyphos has engineered the NKG2D receptor inactive until a bispecific is administered, enabling the NKG2D receptor to bind to a tumour antigen. Xyphos' method could also be used when mutating cancer cells render them unable to recognise their own antigens or other foreign proteins.
Xyphos Biosciences has partnered with The Parker Institute for Cancer Immunotherapy to improve the safety and effectiveness of first-generation CAR-T therapies. Xyphos has engineered the NKG2D receptor inactive until a bispecific is administered, enabling the NKG2D receptor to bind to a tumour antigen. Xyphos' method could also be used when mutating cancer cells render them unable to recognise their own antigens or other foreign proteins.